Codeine
Prodrug opioid analgesic that is O-demethylated to morphine by CYP2D6. Analgesic effect depends on CYP2D6 phenotype: poor metabolizers get little benefit, ultrarapid metabolizers risk toxicity. ~10% of dose converted to morphine.
Projected serum levels — 30 mg, as needed (shown daily)
Maintenance schedule: 30 mg as needed (shown daily) (oral).
Modeled steady state after ~1 days: peak ≈ 21.3 mg, trough ≈ 0.12 mg body load. Population-based estimate over 15 days for a 30 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Opioid
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 3 h
- Common dose
- 30 mg
- Suggested maximum
- 240 mg/day
- Reference dose range
- 15–240 mg (single dose)
- Suggested cadence
- as needed (shown daily)
- Validated against
- 60 mg oral — Cmax 0.14 mg/L at 1 h
Documented interactions
-
danger
1,4-BDO (1,4-Butanediol) + Codeine
1,4-BDO converts to GHB. Codeine metabolizes to morphine. Stacked CNS depression is dangerous.
-
danger
7-Hydroxymitragynine (7-OH) + Codeine
7-Hydroxymitragynine is a potent mu-opioid agonist. Codeine is metabolized to morphine. Combined mu-agonism creates additive respiratory depression risk.
-
danger
CBD (Cannabidiol) + Codeine
CBD (Cannabidiol) reversible_inhibitor of UGT2B7 predicted to change Codeine AUC by ~2.11x
-
danger
Cocaine + Codeine
Stimulant + opioid combination: cocaine masks sedation, increasing overdose risk.
-
danger
Ethanol (Alcohol) + Codeine
Alcohol potentiates opioid respiratory depression. Codeine is metabolized to morphine; alcohol increases CNS depression.
-
danger
Gabapentin (Neurontin) + Codeine
Gabapentin + opioids significantly increases respiratory depression risk. FDA black box warning.
Serum checks 72 modeled interaction pairings for codeine across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Pharmacokinetics of Codeine and Its Metabolite Morphine in Ultra-Rapid Metabolizers due to CYP2D6 Duplication
Measured codeine and morphine pharmacokinetics over 24 h in CYP2D6 ultra-rapid metabolizers, showing significantly higher morphine exposure due to gene duplication.
-
Codeine Intoxication Associated with Ultrarapid CYP2D6 Metabolism
Case report and pharmacogenetic analysis showing life-threatening opioid intoxication from codeine in a CYP2D6 ultrarapid metabolizer due to excessive morphine formation.
-
Codeine and Morphine in Extensive and Poor Metabolizers of Sparteine: Pharmacokinetics, Analgesic Effect and Side Effects
Compared codeine-to-morphine conversion in CYP2D6 extensive vs poor metabolizers, demonstrating that poor metabolizers produce negligible morphine and have reduced analgesia.
3 published studies referenced in the app, each with a plain-language summary.